ActivBiotics, Inc.
www.activbiotics.com
 
ActivBiotics is focused on the development and commercialization of antibacterials for the treatment of acute and chronic disease. The Company is developing rifalazil - a potent broad spectrum antibiotic that targets and inhibits the transcriptional machinery of bacteria.

A&G Pharmaceutical, Inc.
www.agrx.net
 
A&G Pharmaceutical, Inc., is a privately held biotechnology company with advanced programs in cancer diagnostics and therapeutics. In addition A&G's antibody division has developed several antibodies for clients and has become recognized by organizations such as NIH as one of the fastest and best mouse monoclonal antibody developers in the world. Over the last three years A&G has become the preferred partner for more than 14 biotech and pharmaceutical companies in monoclonal antibody development.

AtriCure, Inc.
www.atricure.com (NASDAQ:ATRC)
 
AtriCure develops, manufactures and markets products for the surgical treatment of atrial fibrillation (AF). Its technology is the first in a new category of bipolar radiofrequency energy and allows a surgeon to cure atrial fibrillation either as an adjunct to an existing cardiothoracic procedure or as a stand-alone minimally invasive procedure. AtriCure's technology offers a simple, minimally invasive cure for AF by providing the necessary transmural (or full thickness) lines of electrical blockage in the atrium both safely and simply in open and minimally invasive procedures. The Company's technology allows the surgeon to perform a curative procedure in 15 minutes as an adjunct to an open procedure, or in one hour as a stand-alone minimally invasive procedure.

Biodel, Inc.
www.biodel.com
 
Biodel Inc. is a biopharmaceutical drug delivery company. Biodel develops drug delivery technologies that increase drug efficacy, enhance drug performance, and make drugs easier for patients to take. This technology is applicable to a wide range of peptides, proteins and other macromolecules. Using this technology, Biodel has developed a novel drug formulation of recombinant human insulin designed to speed the delivery of insulin into the blood called Viaject^TM to treat patients with Type 1 and Type 2 diabetes.

Biopure Corporation
www.biopure.com (NASDAQ: BPUR)
(Realized)
 
Biopure's product is a "blood substitute," or more properly defined as a hemoglobin- based oxygen carrier (HBOCs). The hemoglobin is derived from a bovine source. The product is universally compatible, requiring no blood-typing or cross-matching, and virtually eliminates the risk of transmission of diseases such as AIDS or hepatitis. Biopure has two major products: Hemopure for human use and Oxyglobin for veterinary use. The human product is in final stages of clinical trails and the F.D.A. has approved the veterinary product.

Callisto Pharmaceuticals, Inc.
www.callistopharma.com (AMEX:KAL)
(Partially Realized)
 
Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. One of the Company's lead drug candidates, currently in the clinic, L-Annamycin, is being developed as a treatment for forms of relapsed leukemia, a currently incurable blood cancer. Another anti-cancer drug, Atiprimod, also in the clinic, is in development to treat relapsed multiple myeloma, a blood cancer. Callisto also has drugs in preclinical development for gastro-intestinal inflammation, and a program focused on the development of a drug to protect against Staphylococcus and Streptococcus biowarfare agents.

Cequent Pharmaceuticals, Inc.
www.cequentpharma.com
 
Cequent has a powerful and extensible technology platform for treating GI disorders. Furthermore, the company, with its unique solution to both manufacturing and delivery, is an attractive acquisition target for the many publicly-traded RNAi companies, such as Alnylam and Sirna. Cequent was founded to commercialize the discoveries of Dr. Chiange Li while at Harvard-BIDMC. The company is developing a novel therapeutic probiotic which delivers inhibitory RNA directly to the gut for the treatment of a variety of gastrointestinal disorders such as irritable bowel disease, Crohn’s disease, familial polyposis (pre-colon cancer) and colon cancer. The technology elegantly addresses the extant challenges associated with RNAi- delivery and manufacturing. More specifically, the technology exploits the ability of certain bacteria to both penetrate into diseased tissue and, once there, produce and deploy therapeutically functional RNAi in situ. The first indication to be pursued is familial polyposis (FP), a genetic disease that leads to scores of precancerous polyps in the large intestine. Currently, FP is largely untreatable and nearly 100% of patients progress to metastatic colon cancer. Cequent is the first company to generate in vivo data showing the utility of genetically modified, probiotic bacteria producing RNAi to ameliorate the disease. This data was published in the scientific journal Nature Biotechnology. Cequent recently signed a major equity investment and collaboration agreement with Novartis.

Curis, Inc.
www.curis.com (NASDAQ: CRIS)
 
Curis, Inc. is developing products that define an emerging area of biotechnology known as regenerative medicine. These products are designed to recreate the conditions that support the growth of cells and tissue by focusing in the signaling pathways regulating cellular development, and thereby to harness the body's inherent ability to repair damage caused by disease, trauma, or age.

Cutanea Life Sciences, Inc.
www.cutanealife.com
 
Cutanea Life Sciences is a development stage specialty pharmaceutical company whose mission is to strategically in-license novel, mid-stage candidates to treat diseased and aging skin conditions, aggressively advance their development and maximize intellectual property and therapeutic applications, in order to create market-leading products for out-license or commercialization. Cutanea currently has in-licensed three novel product candidates: a rosacea drug currently in Phase II clinical development, a dermal filler with a planned CE mark approval in 2008 and a topical antiviral with clinical trials initiating in late 2007 or early 2008.

Delcath Systems, Inc.
www.delcath.com (NASDAQ: DCTH)
 
Delcath has developed a system to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver. Using the Delcath system to deliver chemotherapy to the liver and cleanse the blood of the chemotherapy before its return from the liver into the patient's circulatory system protects other parts of the body from the harmful side-effects of chemotherapy. The Company believes that the use of the Delcath system in treatment of liver cancer will allow higher dosages of chemotherapy to be administered to the liver than can be administered with conventional intravenous delivery.

Deltex Medical
www.deltexmedical.com (EASDAQ: DLTX)
 
Deltex develops, manufactures, and markets minimally invasive cardiac output monitoring devices. To date, the Company has developed three products, one of which is already being sold in Europe, North America (FDA approved) and Asia. The marketed product is a non-invasive cardiac function monitor, which uses Doppler ultrasound technology.

Diomed Holdings, Inc.
www.diomedinc.com
 
Diomed develops and commercializes minimal and micro- invasive medical procedures that use its proprietary laser technologies and disposable products. Diomed's EVLT(R) laser vein ablation procedure is used in varicose vein treatments. Diomed also provides photodynamic therapy (PDT) for use in cancer treatments, and dental and general surgical applications. Along with lasers and single-use procedure kits for its EVLT(R) laser vein treatment, the Company provides its customers with state of the art physician training and practice development support.

Drew Scientific Group, PLC
(Formerly CDC Technologies, Inc.)
www.drew-scientific.com
(Realized)
 
The Company designs, manufactures and markets low-cost, highly-capable hematology and clinical chemistry analyzers, which provide complete blood test results at the point of care. Drew sells into the human and veterinary markets.

EffRx, Inc.
www.effrx.com
 
EffRx has an exclusive world-wide license from Merck & Co to an effervescent form of FOSAMAX, Merck's $1 billion+ osteoporosis drug. Many patients cannot take Merck's form of FOSAMAX and hence EffRx's more tolerable version can command a significant market share. EffRx has developed and patented an improved effervescent technology that covers most pharmaceutical compounds of commercial significance. EffRx also has a special relationship with a Swiss manufacturer of effervescent drugs that will supply its needs for the foreseeable future. It has already formulated the product for clinical trials in the US and Europe that it anticipates launching during the next 12 months.

Energetiq Technology, Inc.
www.energetiq.com
 
Energetiq was founded in March, 2004 with a mission to be the preeminent developer and manufacturer of short wavelength light sources for use in the analysis and fabrication of nano-scale structures and products. Energetiq's goal is to leverage its substantial expertise to develop novel, cost effective, short wavelength light sources that will enable the production of next generation devices to be used in lithography, metrology, inspection, thin-film processing and Soft X-Ray Microscopy and a variety of applications where synchrotron radiation has traditionally been used in biological imaging markets.

EyeGate Pharmaceuticals, Inc.
www.eyegatepharma.com
 
EyeGate Pharma is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGate® II. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both preclinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic disease or diseases in the mid and posterior segments of the eye is less than adequate. We believe the EyeGate® II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease. Eyegate is a platform technology based on electro-transport that focuses on the development of innovative devices to treat intraocular diseases of the eye such as age related macular degeneration, diabetic retinopathy, chronic macular edema, and posterior uveitis. Several drugs have been tested over the years in pre-clinical studies and can be delivered by this technology: anesthesics, steroids, NSAIDs, anticancers, antibiotics, antivirals, antifungals and various oligonucleotide constructs including RNAi. Eyegate non-invasively delivers a constant amount of drug to the posterior chamber of the eye, particularly the choroid and the retina. The device is biocompatible, safe and well tolerated.

Harvard Bioscience
www.harvardbioscience.com (NASDAQ: HBIO)
(Realized)
 
The Company acquires and distributes laboratory equipment and products for companies and institutions in the life sciences field.

HealtheTech, Inc.
 
HealtheTech develops, manufactures (through outsourcing), and markets proprietary personal health solutions. Their digital technology systems are directed at important health issues such as weight management, diabetes, asthma, fitness, and nutrition.

IntraBiotics Pharmaceuticals, Inc.
(NASDAQ: IBPI)
(Realized)
 
IntraBiotics is a biopharmaceutical company developing novel antibacterial pharmaceuticals for the treatment and prevention of serious infectious diseases. The Company is currently focused on completion of clinical testing for a lead compound addressing ventilator associated pneumonia.

LifePoint, Inc.
(AMEX: LFP)
(Realized)
 
Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.

Magellan Biosciences, Inc.
www.magellanbio.com
 
Magellan serves the worldwide clinical-diagnostics market with rapid point-of-care analyzers and automated systems for near-patient testing. Scientists use the Company's discovery systems and sensors for cutting-edge research to develop a new understanding of health and illness — from disease pathology to biomarker identification. Magellan serves customers through wholly owned subsidiaries: ESA Biosciences, Dynex Technologies, and TekCel.

Medivance, Inc.
www.medivance.com
 
Medivance is a medical device company engaged in development of non-invasive therapeutic temperature management methods for patients undergoing critical surgery. The Arctic Sun 2000 represents a new non-invasive approach to therapeutic temperature management. The Arctic Sun System rapidly induces mild hypothermia in those patients who would benefit from therapeutic hypothermia or rapidly reduces temperature in febrile patients.

Memory Pharmaceuticals Corp.
www.memorypharma.com (NASDAQ:MEMY)
 
Memory Pharmaceuticals is highly specialized in the discovery and development of innovative treatments for learning and memory impairments associated with disease and aging. Memory has a fundamental understanding of the molecular pathways involved in forming new memories based on the pioneering scientific achievements of its distinguished co-founder and 2000 Nobel Laureate, Eric Kandel. Memory has built a state-of-the-art platform interfacing highly specialized medicinal chemistry, biological and drug development disciplines to rapidly produce clinically relevant drug candidates.

Memry Corporation
www.memry.com (AMEX: MRY)
 
Memry Corporation is an advanced materials company engaged in the business of developing, manufacturing and marketing semi-finished materials, formed components and value-added sub-assembled products utilizing the properties exhibited by shape memory alloys, primarily those composed of nickel titanium (nitinol). The Company sells its products and services primarily to the medical device (especially stents, guidewires and laparoscopic subassemblies), telecommunications, aerospace and automotive industries.

Minrad, Inc.
www.minrad.com (AMEX:BUF)
 
Minrad is an acute care medical device and pharmaceutical company with an emphasis in minimally invasive head, neck and spine surgeries and pain management. The Company has 3 separate but inter-related businesses: selling generic inhalation anesthetics in fifteen countries; laser guided devices, and disposables, for minimally invasive surgery; and an emerging conscious sedation device to deliver anesthetics. Management team of successful innovators (21 510K clearances, 12 patents issued).

MSO Medical
(OTC BB: MSO.OB)
 
MSO is an Obesity Disease Management (ODM) Company that manages the provision of two treatment options for obesity. The first is a non-interventional weight-loss treatment through telephonic behavioral coaching by licensed behavioral healthcare professionals. The second is a surgical option which includes gastric bypass surgery performed at Centers for Obesity Related Illness which MSO manages at certain acute care hospitals in the United States.

mtm Laboratories, AG
www.mtm-laboratories.com
 
mtm laboratories is a certified developer and manufacturer of In-vitro Diagnostics for screening and diagnosis of cervical cancer with products marketed world-wide. mtm's products target the largest existing screening market in oncology. The biomarker-based diagnostic assays promise to be more cost-effective and to offer superior sensitivity and specificity compared to conventional screening methods for identifying cervical pre-cancerous and cancerous lesions.

Myconostica, Ltd.
www.myconostica.co.uk
 
Myconostica's assays represent a novel application of molecular diagnostics to the area of infectious fungal disease. The first product will provide an assay to detect infectious fungi of the respiratory tract and will provide a result within hours providing a clear clinical utility summarized as:

• Faster diagnosis with a better clinical outcome
• Reducing missed diagnoses
• Cost savings in drugs and hospital stay

Neurotech, Inc.
www.neurotechusa.com (OTC BB: MSO.OB)
 
Neurotech is dedicated to the development of sight-saving therapeutics for chronic retinal diseases. Neurotech's lead product (NT-501) is in clinical development for the treatment of retinal degeneration, including retinitis pigmentosa, an inherited disease leading to blindness, and the dry form of age related macular degeneration. Neurotech is also evaluating other factors that can be used with its proprietary delivery technology, Encapsulated Cell Technology, to treat additional retinal diseases.

Omnisonics Medical Technologies, Inc.
www.omnisonics.com
 
OmniSonics Medical Technologies, Inc. is developing breakthrough treatments for peripheral and coronary vascular occlusive disease. Its breakthrough products are based on its innovative OmniWave™ acoustic technology, the first technology that enables the delivery of acoustic energy over the active length of a small diameter (0.004") wire in an occluded vessel. European CE mark, US IDE pivotal trial underway. Trials are consistently showing resolution of plaque, clot, etc., to sub-10 micron (i.e. red blood cell size).

Panacos Pharmaceuticals
www.panacos.com (NASDAQ:PANC)
(Partially Realized)
 
Panacos Pharmaceuticals is developing the next generation of antiviral drugs for the treatment of Human Immunodeficiency Virus (HIV) infection and other major viral diseases. Our proprietary discovery technologies focus on novel targets in the virus life cycle, including the first and last steps of virus infection.

Predix Pharmaceuticals, Inc.
 
The Company, successor to a merger with Physiome Sciences, is a drug discovery and development company with an integrated computational and medicinal chemistry platform to accelerate drug generation by modeling specific molecules, cells and organs (e.g., the heart). With a current focus on G-protein coupled receptors, the Company is ready to go into the clinic with a drug addressing anxiety and depression, and is in animal studies with a drug addressing pulmonary hypertension.

Presidio Pharmaceuticals, Inc.
www.presidiopharma.com
 
Presidio Pharmaceuticals, Inc. is building a sustainable specialty pharmaceutical company focused on development and commercialization of novel small molecule antiviral therapeutics. It has three programs ongoing, with the latest expected to complete its first human clinical trial, in HIV, by Q-1 2008. Its lead compound is a nucleoside reverse transcriptase inhibitor (NRTI) with a novel "penultimate chain termination" mechanism. This compound shows preclinical efficacy against HIV, cytomegalovirus (CMV), and hepatitis B virus (HBV). Presidio is also developing small molecules for HIV and influenza based on its proprietary Nuclear Exclusion Technology (NEXT™) platform. This is a novel viral targeting mechanism that inhibits the importation of viral RNA and DNA into the nucleus of the cell, impeding a critical step in virus replication. In addition, the company has licensed a program from Stanford University to develop small-molecule compounds against two novel targets for HCV.

Sabal Medical, Inc.
www.sabalmedical.com
 
Sabal Medical, Inc. is a developer and manufacturer of proprietary medication safety solutions. The Sabal Solution is a closed-loop system ensuring the 5-Rights of Patient Safety: Right Patient, Right Medication, Right Dose, Right Time, and Right Route. The Company's highly differentiated and patent-protected Palmetto™ mobile cabinet and Palmetto Point of Care Software replaces traditional medication cabinets, mobile medication carts and stand-alone point of care software. The technology employed is electro-mechanical components designed and engineered for this special application. There is no major leap in technology here. The products are a portable hardware unit and software, sold separately. The customers are hospitals that have already adopted unit dose dispensing (a majority of US hospitals). Sabal claims that its unit is the smallest, lightest and most maneuverable system for delivering all medications to the patient's bedside safely. Since the storage containers are accessed directly by software, there is no need for an additional keypad locking system. Medication access can be accomplished by using a variety of computing platforms, and wireless connectivity is standard.

Santarus, Inc.
www.santarus.com (NASDAQ:SNTS)
(Realized)
 
Santarus is a specialty pharmaceutical company focused on acquiring, developing and commercializing products for the prevention and treatment of gastrointestinal diseases and disorders. The Company will develop and market proprietary products which are based on currently marketed products or compounds that have clinically demonstrated safety and efficacy thereby reducing development and regulatory risks and enhancing market acceptance of the products.

Stheno Corporation
www.sthenocorp.com
 
Stheno is developing and commercializing non-contact chemical detectors and detection systems. The first product is a magneto-optical enantiomeric detector (MOPED) for measuring chiral molecules that will be targeted at R&D and process control for the pharmaceutical, fine chemical and food & beverage manufacturing industries.